QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   3.99 (+2.05%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.07 (+0.25%)
MU   111.93 (-3.78%)
GE   152.95 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.86 (-0.07%)
AMC   2.93 (-1.68%)
PFE   25.39 (-0.16%)
PYPL   62.10 (-1.83%)
XOM   118.46 (-0.14%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   3.99 (+2.05%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.07 (+0.25%)
MU   111.93 (-3.78%)
GE   152.95 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.86 (-0.07%)
AMC   2.93 (-1.68%)
PFE   25.39 (-0.16%)
PYPL   62.10 (-1.83%)
XOM   118.46 (-0.14%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   3.99 (+2.05%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.07 (+0.25%)
MU   111.93 (-3.78%)
GE   152.95 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.86 (-0.07%)
AMC   2.93 (-1.68%)
PFE   25.39 (-0.16%)
PYPL   62.10 (-1.83%)
XOM   118.46 (-0.14%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   3.99 (+2.05%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.07 (+0.25%)
MU   111.93 (-3.78%)
GE   152.95 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.86 (-0.07%)
AMC   2.93 (-1.68%)
PFE   25.39 (-0.16%)
PYPL   62.10 (-1.83%)
XOM   118.46 (-0.14%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
$3.27
-2.4%
$4.00
$0.92
$16.95
$62.27M0.481.52 million shs682,179 shs
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
$4.51
+2.0%
$5.38
$4.25
$12.75
$162.59M0.06229,265 shs217,741 shs
Selecta Biosciences, Inc. stock logo
SELB
Selecta Biosciences
$1.06
$0.81
$1.99
$136.76M0.84979,585 shs2.77 million shs
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$4.80
-0.8%
$8.11
$4.43
$100.80
$5.90M0.7411,852 shs11,001 shs
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
$24.74
+2.4%
$17.92
$7.38
$39.60
$74.47M0.5664,549 shs3,423 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
0.00%-9.95%-7.97%-16.46%-9.46%
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
-5.35%-7.53%-19.49%-23.26%-57.72%
Selecta Biosciences, Inc. stock logo
SELB
Selecta Biosciences
0.00%0.00%0.00%0.00%-27.77%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
+1.68%-28.72%-40.98%-37.14%-94.74%
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
+0.08%-4.55%+20.75%+183.45%-19.51%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
3.1805 of 5 stars
3.51.00.04.50.01.70.6
Selecta Biosciences, Inc. stock logo
SELB
Selecta Biosciences
2.1538 of 5 stars
3.30.00.04.50.62.50.6
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/AN/AN/AN/AN/AN/AN/AN/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
N/AN/AN/AN/A
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
3.00
Buy$19.33328.68% Upside
Selecta Biosciences, Inc. stock logo
SELB
Selecta Biosciences
2.50
Moderate Buy$2.80∞ Upside
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/AN/AN/AN/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
N/AN/AN/AN/A

Current Analyst Ratings

Latest VCNX, VTVT, MLND, SCPH, and SELB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/14/2024
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
N/AN/AN/AN/A$1.78 per shareN/A
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
$13.59M11.96N/AN/A$1.04 per share4.34
Selecta Biosciences, Inc. stock logo
SELB
Selecta Biosciences
$110.78M0.00N/A9.91$0.61 per share0.00
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$570K10.36N/AN/A($2.59) per share-1.85
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
$2.02M36.87N/AN/A($9.27) per share-2.67

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
-$36.41MN/A0.00N/AN/A-91.03%-72.44%N/A
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
-$54.81M-$1.42N/AN/AN/A-403.22%-97.18%-49.59%5/8/2024 (Estimated)
Selecta Biosciences, Inc. stock logo
SELB
Selecta Biosciences
$35.38M-$0.22N/AN/AN/A-72.04%-44.13%-22.00%N/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
-$20.25M-$100.86N/AN/AN/A-2,667.31%-571.70%5/20/2024 (Estimated)
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-$20.25M-$10.07N/AN/AN/AN/A-104.93%5/9/2024 (Estimated)

Latest VCNX, VTVT, MLND, SCPH, and SELB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/13/2024Q4 2023
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
-$0.42-$0.35+$0.07-$0.35$6.10 million$6.10 million
3/13/2024Q4 2023
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
N/A-$1.67-$1.67-$1.67N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
N/AN/AN/AN/AN/A
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
N/AN/AN/AN/AN/A
Selecta Biosciences, Inc. stock logo
SELB
Selecta Biosciences
N/AN/AN/AN/AN/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/AN/AN/AN/AN/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
N/A
6.39
6.39
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
1.04
7.08
6.40
Selecta Biosciences, Inc. stock logo
SELB
Selecta Biosciences
0.21
4.18
4.18
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/A
0.57
0.57
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
N/A
1.00
1.00

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
N/A
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
89.52%
Selecta Biosciences, Inc. stock logo
SELB
Selecta Biosciences
41.95%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
50.11%
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
17.51%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
1219.04 millionN/ANot Optionable
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
13536.05 million34.37 millionOptionable
Selecta Biosciences, Inc. stock logo
SELB
Selecta Biosciences
64155.20 million106.78 millionOptionable
Vaccinex, Inc. stock logo
VCNX
Vaccinex
381.23 million598,000Optionable
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
163.01 million2.96 millionNot Optionable

VCNX, VTVT, MLND, SCPH, and SELB Headlines

SourceHeadline
Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Decreases By 43.7%Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Decreases By 43.7%
americanbankingnews.com - April 11 at 2:52 AM
CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMITCANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT
finance.yahoo.com - March 19 at 2:34 PM
vTv Therapeutics Inc.: vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate UpdatevTv Therapeutics Inc.: vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
finanznachrichten.de - March 13 at 3:57 PM
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate UpdatevTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
globenewswire.com - March 13 at 8:00 AM
vTv Therapeutics starts phase 3 trial for diabetes drugvTv Therapeutics starts phase 3 trial for diabetes drug
investing.com - March 6 at 4:28 PM
The Top 3 Healthcare Stocks to Buy on Weakness in 2024The Top 3 Healthcare Stocks to Buy on Weakness in 2024
investorplace.com - March 4 at 3:49 PM
vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 DiabetesvTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes
globenewswire.com - March 4 at 8:00 AM
vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare ConferencevTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference
globenewswire.com - March 1 at 8:00 AM
vTv Therapeutics stock doubles after raising $51 million from health care investors including JDRFvTv Therapeutics' stock doubles after raising $51 million from health care investors including JDRF
bizjournals.com - February 29 at 7:40 AM
Why Is Diabetes Focused vTv Therapeutics Stock Trading Higher Today?Why Is Diabetes Focused vTv Therapeutics Stock Trading Higher Today?
msn.com - February 28 at 6:07 PM
vTv Therapeutics Inc. (VTVT)vTv Therapeutics Inc. (VTVT)
finance.yahoo.com - February 28 at 6:07 PM
Nasdaq Down 50 Points; US Crude Stocks Rise By 4.2M BarrelsNasdaq Down 50 Points; US Crude Stocks Rise By 4.2M Barrels
markets.businessinsider.com - February 28 at 1:07 PM
VTv Therapeutics Shares Surge on $51 Million Private PlacementVTv Therapeutics Shares Surge on $51 Million Private Placement
marketwatch.com - February 28 at 1:07 PM
vTv Therapeutics Inc. Cl AvTv Therapeutics Inc. Cl A
wsj.com - February 28 at 8:06 AM
vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D FundvTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund
finance.yahoo.com - February 28 at 8:06 AM
vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D FundvTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund
globenewswire.com - February 28 at 8:00 AM
CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCECANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE
prnewswire.com - February 22 at 4:00 PM
vTv Therapeutics Inc (VTVT)vTv Therapeutics Inc (VTVT)
uk.investing.com - January 31 at 8:11 AM
BRIEF—Huadong intends to withdraw from vTv collabBRIEF—Huadong intends to withdraw from vTv collab
thepharmaletter.com - December 28 at 10:03 AM
vTv Therapeutics Inc - Ordinary Shares - Class AvTv Therapeutics Inc - Ordinary Shares - Class A
money.usnews.com - November 27 at 7:11 PM
vTv Therapeutics (NASDAQ: VTVT) to jump 4,000% - no, just a technical, nominal, movevTv Therapeutics (NASDAQ: VTVT) to jump 4,000% - no, just a technical, nominal, move
dhakatribune.com - November 21 at 10:54 PM
vTv Therapeutics regains compliance with Nasdaq after 1-for-40 reverse stock splitvTv Therapeutics regains compliance with Nasdaq after 1-for-40 reverse stock split
bizjournals.com - November 21 at 5:53 PM
vTv Therapeutics loses $6.7M in Q3, could lose spot on NASDAQ indexvTv Therapeutics loses $6.7M in Q3, could lose spot on NASDAQ index
bizjournals.com - November 15 at 1:32 PM
vTv Therapeutics Stock (NASDAQ:VTVT) Earnings Dates and Earning CallsvTv Therapeutics Stock (NASDAQ:VTVT) Earnings Dates and Earning Calls
benzinga.com - November 11 at 8:11 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Millendo Therapeutics logo

Millendo Therapeutics

NASDAQ:MLND
As of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.
scPharmaceuticals logo

scPharmaceuticals

NASDAQ:SCPH
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
Selecta Biosciences logo

Selecta Biosciences

NASDAQ:SELB
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
Vaccinex logo

Vaccinex

NASDAQ:VCNX
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester, New York.
vTv Therapeutics logo

vTv Therapeutics

NASDAQ:VTVT
vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes that is in Phase III clinical trial; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases, psoriasis, COPD, and Atopic Dermatitis that is in Phase III clinical trial. It also develops TTP273, an orally available, small molecule glucagon-like peptide 1 receptor agonists for the treatment of cystic fibrosis related diabetes that is in Phase I clinical trial. In addition, the company is involved in the clinical development of other programs, including HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application in humans; and with Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator; with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.